anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a self-report survey utilizing a voluntary, non-probability sampling design. The survey instrument will be created in Google Survey© consisting of yes/no, multiple choice and free text response questions. This survey instrument questions have been developed empirically by the investigators.

It will be distributed to all gastroenterology fellowship coordinators through an email listserv maintained by programs nationwide for the purpose of communicating with their trainees. The email will include instructions to share the survey link (Appendix 2) with all first/second/third year as well as all advanced gastroenterology fellow s in their programs. The survey will be disseminated over a 2 week period. The fellowship coordinator will receive three separate emails. The first email (Appendix 2) will be on opening day of the survey requesting them to forward the link to their fellows. The second email (Appendix 3) will be sent on day 8 of the study period serving as a reminder to participate in the survey with link once again attached. The final email (Appendix 4) will be distributed on day 14 of the study period serving as a final reminder for fellows to complete the survey if they have not already and that the survey will close at midnight. The link will have both the informed consent form and the survey. Participants must press a key indicating agreement to get past the consent to the survey. The survey will take less than 2 minutes to complete electronically. This will be an anonymous survey and will be distributed via a secure online platform.

The results will be compiled using Google Survey© software. No personal identifying information will be included.
INTRODUCTION AND BACKGROUND: Intimate partner violence (IPV) and child malnutrition are global public health issues. Assessing the association between IPV and child anthropometric failures (stunting, underweight, and wasting) in 29 Sub-Saharan African (SSA) countries can provide significant global health solutions. Some studies have found an association between IPV against women and child malnutrition, but the conclusions are inconsistent. The physical and psychological conditions, living environment, and rights of the mother may be involved.
METHODS: We collected and analyzed the Demographic and Health Surveys data (2010-2021) of 29 SSA countries. The main exposure variables were various types of IPV, classified as physical, sexual, and emotional violence. The outcome was the child's development index, which can be roughly divided into stunting, wasting, and underweight. An adjusted binary logistic regression model was used to test the relationship between IPV and children's nutritional status.
RESULTS: A total of 186,138 children under 5 years of age were included in the analysis; 50,113 (27.1%) of the children were stunted, 11,329 (6.1%) were wasted, and 39,459 (21.3%) were underweight in all regions. The child's gender, age, duration of breastfeeding, complementary feeding, and vitamin A supplements intake in the past 6 months were associated with their nutritional status (p < 0.001). Sexual violence was the strongest factor associated with stunting, which remained statistically significant after controlling all variables (AOR = 1.11; 95% CI: 1.02, 1.21; p = 0.012). We also found a small negative association between wasting and IPV. For underweight, there were no associations with IPV after controlling for all variables (p > 0.05).
CONCLUSION: IPV is positively associated with child stunting in SSA countries. Sexual violence showed a strong positive correlation with stunting. Wasting was unexpectedly negatively associated with IPV. There was no clear correlation between underweight and violence.
The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Alcohol, in particular, has been found to exhibit additive effects of this variety.

Concomitant use of Nitroglycerin Transdermal Systems with phosphodiesterase inhibitors in any form is contraindicated (see CONTRAINDICATIONS).

Concomitant use of Nitroglycerin Transdermal Systems with riociguat, a soluble guanylate cyclase stimulator, is contraindicated (see CONTRAINDICATIONS).

Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination. Dose adjustments of either class of agents may be necessary.
Quinolinomorphinane derivatives represented by the following general formula (I) or pharmacologically acceptable acid addition salts thereof and remedies and preventives for brain disorders containing the same. In said formula, R1 represents cyclopropylmethyl, etc.; R?2 and R3¿ represent each hydroxy, methoxy, etc.; R4 represents hydrogen, methyl, amino, etc.; and (R5)m represents hydrogen, substituted benzo, etc. Because of having excellent preventive effects on cranial nerve cell disorders, these compounds inhibit various ischemic, hemorrhagic or traumatic brain disorders and cranial nerve cell disorders caused by various nerve degenerations and are thus useful as drugs for treating and preventing various brain diseases such as cerebral stroke, traumatic brain diseases, brain edema and cranial nerve degeneration diseases, ameliorating the after troubles of these diseases and preventing the recurrence of the same.
Lafora disease (LD; OMIM#254780) is a rare, devastating, and fatal form of progressive myoclonus epilepsy that affects young adolescents and has no treatment yet. One of the hallmarks of the disease is the accumulation of aberrant poorly branched forms of glycogen (polyglucosans, PGs) in the brain and peripheral tissues. The current hypothesis is that this accumulation is causative of the pathophysiology of the disease. Another hallmark of LD is the presence of neuroinflammation. We have recently reported the presence of reactive glia-derived neuroinflammation in LD mouse models and defined the main inflammatory pathways that operate in these mice, mainly TNF and IL-6 signaling pathways. In addition, we described the presence of infiltration of peripheral immune cells in the brain parenchyma, which could cooperate and aggravate the neuroinflammatory landscape of LD. In this work, we have checked the beneficial effect of two compounds with the capacity to ameliorate neuroinflammation and reduce leukocyte infiltration into the brain, namely fingolimod and dimethyl fumarate. Our results indicate a beneficial effect of fingolimod in reducing reactive astrogliosis-derived neuroinflammation and T-lymphocyte infiltration, which correlated with the improved behavioral performance of the treated Epm2b-/- mice. On the contrary, dimethyl fumarate, although it was able to reduce reactive astrogliosis, was less effective in preventing neuroinflammation and T-lymphocyte infiltration and in modifying behavioral tests.
Arm B consists of the multimodal CROSS arm, which includes a combination of chemotherapy and radiotherapy prior to surgery. The patient will receive four and a half (4.5) weeks of radiation therapy (41.4 Gy/23 fractions), and 5 weekly cycles of chemotherapy. The chemotherapy and radiotherapy will run concurrently over a 4 and a half-week period. Chemotherapy is given by intravenous infusion on days 1, 8, 15, 22 and 29. The radiation will generally commence on the 1st day of treatment and will run for 4 and a half weeks as follows: days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31 inclusive.
The invention provides materials, devices and methods for marking biopsy sites for a limited time. The biopsy-marking materials are ultrasound-detectable bio-resorbable powders, with powder particles typically between about 20 microns and about 800 microns in maximum dimension, more preferably between about 300 microns and about 500 microns. The powders may be formed of polymeric materials containing cavities sized between about 10 microns and about 500 microns, and may also contain binding agents, anesthetic agents, hemostatic agents, and radiopaque markers. Devices for delivering the powders include tubes configured to contain the powders and to fit within a biopsy cannula, the powders being ejected by action of a syringe. Systems may include a tube containing powder, and a syringe containing sterile saline. The tube may be configured to fit within a biopsy cannula such as a Mammotome® or SenoCor 360.TM. cannula.
PURPOSE: To obtain the subject improver containing antithrombin-III of human origin as active ingredient, having placenta blood stream-improving action, and esp. effective for treating e.g. fetus development retardation in the uterus due to blood stream lowering. CONSTITUTION: This placenta blood stream improver contains antithrombin-III of human origin as active ingredient, and is formulated, into preparations such as powder, granules, tablets, capsules, syrup, injection, etc., by appropriately blending conventional additive(s) stabilizer, etc., thereto. Its daily dose is pref. 1-1000 units/kg body weight of adult (e.g. for intravenous administration, pref. 10-100 units). Increase in placenta blood stream enables a fetus to be protected during disease and to be developed normally in the mother, and this improver is highly safe to both mother and its fetus. The antithrombin-III can be purified from e.g. human whole blood, plasma, serum, or the serum obtained by squeezing coagulated blood, and is esp. pref. negative to HBs antigen, anti-HIV antibody and not higher than double the normal GTP value.
The invention discloses a traditional Chinese medicine pill for eliminating stagnation stomachache, which is prepared from the following components in parts by weight: the invention relates to a traditional Chinese medicine composition for treating depression, which is prepared from 14 traditional Chinese medicines of salvia miltiorrhiza, radix bupleuri, coptis chinensis, immature bitter orange, dried ginger, corydalis tuber, white paeony root, rhizoma salviae miltiorrhizae, codonopsis pilosula, rhizoma cyperi, sandalwood, cuttle bone, fructus amomi, liquorice and the like. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has effects in regulating normal physiological function of liver, spleen and stomach, clearing away heat, regulating stomach function, dispersing depressed liver-energy, lowering adverse qi, promoting qi circulation, relieving oppression, nourishing blood, invigorating spleen, dispersing liver-qi, promoting spleen qi production, lowering stomach qi, and regulating yin and yang. 4. Can be used for treating reflux esophagitis and improving symptoms and signs of chronic stomach.
This pilot study aims at comparing the bioavailability of three different formulations of a combination of omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a standardized proportion of 460:200. The three formulations are ethyl ester (EE), triglyceride (TG) and monoglyceride (MAG) versions of these fatty acids. The formulations are prepared in a way to be similar in proportion of EPA/DHA, in dose and in appearance. Thirty six (36) subjects will be divided in three groups of twelve subjects each, equally divided in two study sites. The study will be randomized and double blinded. Each group will be taking one of the three different formulations of EPA+DHA at a daily dose of 1.5g for a period of 12 weeks. Bioavailability will be measured through omega-3 index (total content of EPA + DHA in red blood cell membranes) at baseline and every four weeks during treatment. After recruitment, subjects will be seen in clinic every four weeks for a total of four (4) study visits during which a blood sample will be taken for analysis of the omega-3 index, the investigational product will be returned and dispensed and finally, adverse events will be noted and followed. Treatment will be self-administered by subjects at home. They will be asked to keep a journal of adverse events, concomitant medication and to note every missed dose as well as significant changes in life habits (smoking, alcohol, sports, food diet and natural health products intake).
The process of gait recovery in patients with severe post-stroke hemiplegia requires a significant investment and effort for both the patient and the therapist and is not always leading to a safe and autonomous gait. Increasing the chances for the patients of regaining a functional walking gait within limited timeframes is a challenge. Several studies have focused their attention on the neurological foot in the chronic phase because a poorly controlled foot dorsiflexion is a factor limiting gait recovery and increasing fall risk. Functional Electrical Stimulation (FES) can be used as an alternative to an orthosis to restore walking by activating paralyzed muscles. FES has been extensively studied to correct drop foot by activating foot dorsiflexors or inducing a withdrawal reflex.

Few studies have considered knee joint which has a major role, especially for the quality of the support, and this over the entire cycle of walking. In the initial phase after stroke, ensuring a safe knee control remains difficult because of the associated disorders including the lack of proprioceptive feedback. Classical observed disorders in this population are knee hyperextension during the stance phase (genu recurvatum) and flexed knees (crouch gait). Fixed orthoses are usually used to prevent this by limiting knee flexion or extension over the gait. FES is also an alternative to produce appropriately timed knee flexion or extension. Bioness L300 Plus© device proposes a thigh cuff embedding electrodes stimulating the quadriceps muscles to extend knee at the appropriate time during gait based on shank angle observation. Previous studies have investigated the contribution of quadriceps and gluteus maximus stimulation in improving standing balance and weight transfer or hamstrings stimulation associated to foot dorsiflexors stimulation in improving gait performance.

One of the main objectives of an early rehabilitation is to encourage patients with hemiplegia to rely on their paretic leg and to transfer their weight onto it while walking. Depending on the gait phase, the knee extension and flexion are restricted to a safety range by the adaptive delivery of quadriceps and hamstring electrical stimulation. A sensor network detects gait phases and knee angle evolution from which stimulation levels are modulated.
The intervention group will be subject to RPP. Techniques of slow expiration will be used and slow inspiration for the sweeping of secretions, during its expulsion forced expiratory techniques will be used (tracheal reflex). 10 sessions will be performed, one a day from Monday to Friday, with a duration of 10 to 15 minutes.
Participants with no history of Traumatic Brain Injury, Traumatic Spinal Cord Injury or Intracranial Neoplasm. A single draw of 5 mL of blood will be obtained as well as demographic information and a brief medical history to act as comparison data to the other groups.
A method and apparatus for modeling disease transitions in individuals includes the steps of identifying a population of individuals and defining a disease transition they could undergo. One or more variables are defined that represent medical information collected from these individuals. These variables are considered candidate variables that operate to predict the disease transition to varying degrees of accuracy. A logistic regression technique, along with information stored in an electronic database, are used to determine the degree of accuracy to which each candidate variable predicts the disease transition for the population of individuals. Certain candidate variables are then chosen according to how accurately they predict the disease transition. This set of chosen variables is then used to form a mathematical model, which in turn is used to predict this disease transition for that population of individuals.
During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously for 6 weeks. The dosage for the remaining treatment is dependent of patients response during the induction phase.
Androgenetic alopecia (AGA) is the most prevalent type of hair loss. Its morbility is mainly psychological although an increased incidence in melanoma has also been observed in affected subjects. Current drug based therapies and physical treatments are either unsuccessful in the long term or have relevant side effects that limit their application. Therefore, a new therapeutic approach is needed to promote regenerative enhancement alternatives. These treatment options, focused on the cellular niche restoration, could be the solution to the impact of dihydrotestosterone in the hair follicle microenvironment. In this context emerging regenerative therapies such as Platelet-rich plasma or Platelet-rich fibrine as well as hair follicle stem cells and mesenchymal stem cell based therapies and their derivatives (conditioned medium CM or exoxomes) are highlighting in the evolving landscape of hair restoration. Nanotechnology is also leading the way in AGA treatment through the design of bioinks and nanobiomaterials whose structures are being configuring in a huge range of cases by means of 3D bioprinting. Due to the increasing number and the rapid creation of new advanced therapies alternatives in the AGA field, an extended review of the current state of art is needed. In addition this review provides a general insight in current and emerging AGA therapies which is intented to be a guidance for researchers highlighting the cutting edge treatments which are recently gaining ground.
Vitamin D deficiency and insufficiency are prevalent worldwide, and various factors contribute to their occurrence, including low sun exposure, poor dietary intake, obesity, and abdominal obesity. Abdominal obesity, assessed by waist circumference (WC), is associated with metabolic syndrome and has been linked to low vitamin D levels. This study aimed to investigate the relationship between visceral adipose tissue (VAT) and vitamin D levels, particularly examining the potential threshold for vitamin D storage and sequestration by adipose tissue.

The study is conducted on patients with hypovitaminosis D in an internal medicine outpatient department. Blood samples for the evaluation of calcium and vitamin D levels are collected at baseline and after six months of monthly cholecalciferol supplementation. Ultrasonography are used to evaluate adipose tissue measurements, including subcutaneous adipose tissue thickness, VAT, preperitoneal adipose tissue (PPAT), and prerenal adipose tissue (PRAT). Anthropometric measures such as waist-to-hip ratio and waist-to-height ratio are also assessed.
The participants in the Mirror+Cognitive Therapy will be given a cognitive task with the application of mirror therapy. Cognitive tasks with mirror therapy will be applied in sessions lasting 60 minutes, 3 days a week, over 8 weeks.
BACKGROUND: People with intellectual disabilities (ID) die on an average 20 years earlier to the general population. They have higher rates of multimorbidity and polypharmacy. Around 25% of people with ID report chronic constipation. The England Learning Disabilities Mortality Review found that nearly 25% of deaths identified constipation as a long-term health problem. However, the likely risk factors for constipation related harm are poorly enumerated. We sought to identify possible specific high-risk factors by examining the clinical characteristics of people with ID admitted to hospital with constipation.
METHODS: Data of people with ID admitted with constipation in two general hospitals covering a population of 1.3 million from 2017 to 2022 were reported using the STROBE guideline for cohort studies. Collected data included age, gender, intellectual disability severity, recorded medication, presenting complaint and co-morbidities. The medication anticholinergic burden was calculated using the anticholinergic burden scale. Continuous variables were summarised by mean and standard deviation if normally distributed, with categorical variables summarised by the number and percentage in each category.
RESULTS: Of 46 admissions (males 52%), 57% had moderate to profound ID, 37% had epilepsy, 41% prescribed antiseizure medication (ASM) and 45% were on laxatives. Average age was 46 years. The anticholinergic burden score mean was 2.3 and median, one.
CONCLUSIONS: We can hypothesise that people with more severe ID, suffering from epilepsy and on ASM may be more at risk of developing severe constipation. Some admissions may be avoided with earlier use of laxatives in the community.
PURPOSE:To obtain an organism compatibility promoter containing a compound obtained by treating a protein toxin such as toxin of Vibrio cholerae with an amino group chemically modified substance in a specific ratio as an active ingredient. CONSTITUTION:An organism compatibility promoter containing a compound [e.g. a compound shown by the formula (R1 is toxin of Vibrio cholerae; R2 is chemically modified group obtained by replacing hydrogen atom of primary amino group of protein R1; n is 1-10 with the proviso that n is 1-8 when R1 is viscotoxin)] obtained by treating 1mol. protein toxin selected from toxin of Vibrio cholerae, abrin (obtained from seed of Abrus precatorius L), ricin (protein belonging to albumin having ethanol poison factor and blood aggregation factor) and viscotoxin (peptide toxin contained in Viscum albam L to become a heart toxin) with 1-10mol. chemically modifying substance (e.g. polyethylene oxide) as an active ingredient.
1499240 Ascorbic acid preparations F HOFFMANN-LA ROCHE & CO AG 29 Nov 1976 [30 Nov 1975] 49626/76 Heading C2V [Also in Division A2] A process for the manufacture of stable, dry, free-flowing preparations containing ascorbic acid or a salt thereof, e.g. an alkali or alkaline earth salt, comprises mixing a pre-swollen, non- agglutinating cereal grain e,g. wheat grain, with a concentrated aqueous solution of ascorbic acid or a salt thereof, drying and optionally comminuting the mixture. The preparations suitably have a particle size between 250 Á and 2000 Á and have a vitamin C content of at least 10 wt. per cent which for ascorbic acid may be appropriately 15 to 25 wt. per cent and for sodium ascorbate 25 to 45 wt. per cent. In an example a preparation containing 36 to 38% sodium ascorbate is prepared by heating maize grains and water in an autoclave at 120‹ C.; drying the product at 80‹ C. for 60 minutes; adding a 60% wt./vol. aqueous sodium ascorbate solution; drying the resulting mixture at 60‹ C. under nitrogen at 150 mm./Hg and comminuting the preparation. Use.-These preparations may be mixed with feedstuffs to provide vitaminized feedstuffs in which the vitamin is more stable towards moisture, enzymes and mineral salts which may be present compared with the pure vitamin in similar feedstuffs.